Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Next Deadline
151 days remaining
NOA E-Mailed - SOU Required
Due Date
May 21, 2026
Extension Available
Until November 21, 2026
Application History
27 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 14, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 13, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Nov 13, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Nov 13, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 13, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 12, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 12, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 12, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 11, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 11, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 12, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 12, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 21, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 26, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 26, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 6, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 6, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 16, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 16, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 16, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Feb 16, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 17, 2023 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED | Loading... |
| Nov 17, 2023 | GPRA | F | PRIORITY ACTION E-MAILED | Loading... |
| Nov 17, 2023 | CPRA | R | PRIORITY ACTION WRITTEN | Loading... |
| Nov 14, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 6, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 18, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Therapeutics in the nature of cells, proteins and protein complexes for the treatment and prevention of cancer, inflammation, and inflammatory diseases; biotherapeutics for the treatment and prevention of cancer, inflammation, and inflammatory diseases; medicines for the treatment and prevention of cancer, inflammation, and inflammatory diseases; pharmaceutical products for the treatment and prevention of cancer, inflammation, and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of cells, proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of cells, proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; technology platforms for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
BIOTHERAPEUTICS